The company said that the new schedule builds on the arrangement first announced in May 2024 and pertains to the construction and commissioning of a greenfield drug substance manufacturing facility, referred to as “Unit 2”.
Under the agreement, as per the exchange filing, TheraNym will establish a large-scale mammalian cell culture-based facility with a total bioreactor capacity of 60,000 litres, along with the required downstream purification infrastructure to produce drug substances.
TheraNym will undertake manufacturing at the facility and supply the products to MSD as per the terms of the arrangement. The company plans to invest around $150–175 million in setting up the facility.
In its Q3 FY26 results, the firm had posted a net profit of ₹909.8 crore, up 7.5% year-on-year from ₹846 crore, inclusive of a one-time cost of ₹65 crore due to a change in the labour code.
Its revenue for the quarter grew 8.4% year-on-year to ₹8,646 crore, compared with ₹7,979 crore in the same period last year, supported by growth in Europe and the ARV (Antiretroviral drugs) segment.
Shares of Aurobindo Pharma Ltd ended higher on April 15, with the stock settling at ₹1,375.00 on the NSE, up ₹35.20 or 2.63% for the day. The stock has gained 24% over the past six months.
Also Read: Retail flows stay resilient as MF AUM falls 10.1% MoM in March: Motilal Oswal
